Zylox Medical Device Co
Zylox Medical Device Co., a leading innovator in the medical technology sector, is headquartered in China (CN) and operates extensively across Asia and Europe. Founded in 2010, the company has rapidly established itself as a key player in the development of advanced medical devices, particularly in the fields of minimally invasive surgery and diagnostic imaging. Zylox is renowned for its cutting-edge products, including state-of-the-art endoscopic systems and precision surgical instruments, which are designed to enhance patient outcomes and streamline surgical procedures. The company’s commitment to quality and innovation has earned it numerous accolades, solidifying its position as a trusted name in the medical device industry. With a focus on research and development, Zylox continues to push the boundaries of technology, ensuring it remains at the forefront of medical advancements.
DitchCarbon Score
How does Zylox Medical Device Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zylox Medical Device Co's score of 19 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zylox Medical Device Co's reported carbon emissions
In 2023, Zylox Medical Device Co reported total carbon emissions of approximately 3,291,740 kg CO2e. This figure includes about 279,920 kg CO2e from Scope 1 emissions and approximately 3,011,820 kg CO2e from Scope 2 emissions. The company's emissions have increased from 3,069,870 kg CO2e in 2022 and 1,405,140 kg CO2e in 2021, indicating a rising trend in their carbon footprint over the past three years. Zylox has disclosed emissions data for Scope 1 and Scope 2 but has not provided information on Scope 3 emissions. Despite the increase in total emissions, there are currently no documented reduction targets or climate pledges from the company, which suggests a lack of formal commitments to mitigate their carbon impact. As a medical device manufacturer headquartered in China, Zylox operates in an industry that is increasingly scrutinised for its environmental impact. The absence of specific reduction initiatives or targets may affect its reputation and competitiveness in a market that is progressively prioritising sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 20,840 | 000,000 | 000,000 |
| Scope 2 | 1,384,300 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zylox Medical Device Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
